LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.16

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.13

Max

1.19

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.5M -20M
EPS	-0.32
Angestellte	49
EBITDA	6.8M -22M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+122.5% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	626K 75M
Vorheriger Eröffnungskurs	1.16
Vorheriger Schlusskurs	1.16

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juni 2026, 20:30 UTC

Ergebnisse

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. Juni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Juni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. Juni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. Juni 2026, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. Juni 2026, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. Juni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. Juni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Juni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. Juni 2026, 21:00 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. Juni 2026, 20:46 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:38 UTC

Ergebnisse

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. Juni 2026, 20:21 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:12 UTC

Ergebnisse

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Product Rev $594M

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. Juni 2026, 20:05 UTC

Ergebnisse

Palo Alto Networks 3Q Loss $177M >PANW

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

122.5% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 122.5%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.